Physician profile
John C Gustafson
NPI 1003836016
$406.43
in general payments reported to CMS, 2019-2025
14 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $86.05 · 2023: $143 · 2024: $53.82 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $320.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $57.69 | 2023 | Hawkone |
| Abbott Laboratories | $56.55 | 2022 | |
| Lilly USA, LLC | $47.17 | 2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $38.87 | 2023-2024 | Cologuard Collection Kit |
| Phadia US INC. | $29.50 | 2022 | |
| Boston Scientific Corporation | $27.83 | 2023 | |
| Pfizer INC. | $25.79 | 2023 | |
| Soleno Therapeutics, INC. | $22.49 | 2025 | Vykat Xr |
| Bayer Healthcare Pharmaceuticals INC. | $20.30 | 2024 | |
| Verrica Pharmaceuticals INC. | $17.76 | 2024 | Ycanth |
| Dexcom, INC. | $17.16 | 2025 | Dexcom G6 Transmitter |
| Mayne Pharma Commercial LLC | $16.43 | 2023-2025 | |
| Novo Nordisk INC | $15.20 | 2025 | Wegovy |
| Sage Therapeutics, LLC | $13.69 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gustafson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.